FTC report exposes big pharma middlemen inflating drug prices by up to 7,736%
Report reveals big pharma middlemen inflating drug prices, reaping billions in excess revenue. • The Federal Trade Commission (FTC) released a report showing that pharmacy benefit managers (PBMs) marked up specialty generic drug prices by up to 7,736 percent between 2017 and 2022.
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
CVS Caremark, OptumRx and St. Louis-based Express Scripts — are part of huge health conglomerates that also own insurers, ...
Health care in the US is notoriously complicated and opaque, with a veritable alphabet soup of companies and government agencies that influence how much Americans pay for drugs. Now President ...
The U.S. district judge in Cleveland, Ohio handling a galaxy of claims stemming from the prescription opioid epidemic on ...
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
Field, the longtime manager and co-owner of Rice’s Pharmacy and Gifts, told The Lund Report he continues to lose money on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback